P Farci
Overview
Explore the profile of P Farci including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1982
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanna G, Farci P, Busonera B, Murgia G, La Colla P, Giliberti G
Nat Prod Res
. 2015 Jan;
29(22):2065-70.
PMID: 25613403
Natural products are a successful source in drug discovery, playing a significant role in maintaining human health. We investigated the in vitro cytotoxicity and antiviral activity of extracts from 18...
2.
Mangia A, Antonucci F, Brunetto M, Capobianchi M, Fagiuoli S, Guido M, et al.
Dig Liver Dis
. 2008 Mar;
40(6):395-404.
PMID: 18321798
Molecular assays are instrumental in the clinical management of viral hepatitis. During the past years, a wide variety of molecular assays have been developed and implemented. This considerably improved the...
3.
Farci P, Chessa L, Balestrieri C, Serra G, Lai M
J Viral Hepat
. 2007 Nov;
14 Suppl 1:58-63.
PMID: 17958644
Despite recent advances in the treatment of chronic viral hepatitis, therapy of chronic hepatitis D is not yet satisfactory. The only option currently available is interferon-alpha (IFN), whose efficacy is...
4.
Bonino F, Marcellin P, Lau G, Hadziyannis S, Jin R, Piratvisuth T, et al.
Gut
. 2006 Nov;
56(5):699-705.
PMID: 17127704
Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine...
5.
Hornberger J, Farci P, Prati D, Zeuzem S, Green J, Patel K
J Viral Hepat
. 2006 Jul;
13(6):377-86.
PMID: 16842440
Peginterferon alpha-2a (40 kDa) plus ribavirin is effective at achieving sustained viral response compared with no treatment in patients with chronic hepatitis C (CHC) and persistently normal aminotransferase levels (PNALT)....
6.
Farci P
Clin Liver Dis
. 2001 Nov;
5(4):895-916.
PMID: 11685800
Although recent evidence indicates that the quasispecies nature of HCV constitutes a critical strategy for the virus to survive in the host, the mechanisms of viral persistence remain unknown. Similarly,...
7.
Farci P, Purcell R
Semin Liver Dis
. 2000 Jul;
20(1):103-26.
PMID: 10895435
Hepatitis C virus (HCV) is a major cause of morbidity and mortality worldwide. The infection becomes chronic in about 85% of infected individuals, in the face of a strong humoral...
8.
Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder J, et al.
Science
. 2000 Apr;
288(5464):339-44.
PMID: 10764648
The mechanisms by which hepatitis C virus (HCV) induces chronic infection in the vast majority of infected individuals are unknown. Sequences within the HCV E1 and E2 envelope genes were...
9.
Loviselli A, Oppo A, Velluzzi F, Atzeni F, Mastinu G, Farci P, et al.
J Endocrinol Invest
. 1999 Dec;
22(9):660-5.
PMID: 10595828
To assess the relationship between serological markers of thyroid autoimmunity and chronic hepatitis C, we surveyed the general population of two villages in the region of Sardinia, Italy, where infection...
10.
Polo S, Veglia F, Malnati M, Gobbi C, Farci P, Raiteri R, et al.
AIDS
. 1999 Apr;
13(4):447-54.
PMID: 10197372
Objectives: To investigate the correlation between the serum levels of the CC-chemokines RANTES, macrophage inflammatory protein (MIP)-1alpha and MIP-1beta, and the progression of HIV-1 disease. Design: Retrospective analysis of serial...